Bristol’s R&D marches on
Executive Summary
"I'm pleased to say, R&D marches on," Bristol-Myers Squibb Chief Scientific Officer Elliott Sigal says at a recent strategic alliances conference in New York. "I am glad to be here, actually I'm pleased to get out period," he adds. Bristol's robust pipeline is one reason the firm has been rumored to be an acquisition candidate following the termination of CEO Peter Dolan Sept. 12 on the heels of a failed settlement with Apotex over Plavix generics (1"The Pink Sheet" Sept. 18, 2006, p. 3)...